Stepan Company recently renewed a secretive deal with the US government that lets Coca-Cola produce as much as $3 billion in pure cocaine every year.
The flavor behind Coca-Cola is from coca leaves, the processing of which results in pure cocaine. That processing is done by a small chemical plant in a quiet New Jersey neighborhood, run by Stepan, which has an exclusive license to import coca leaves into the US on behalf of Coca-Cola.
At Stepan’s plant, coca leaves are used to produce a ‘de-cocainised’ ingredient that goes into Coca-Cola.
The cocaine byproduct is then sold to Mallinckrodt, the largest opioid manufacturer in the US, which markets it as a numbing agent and topical anesthetic for dentists.
The Daily Mail stated that Stepan Corporation, the sole American company authorized to import the otherwise prohibited drug, successfully extended its authorization to do so earlier this year.
The amount of coca the corporation imports is still unknown, but the New York Times stated in the 1980s that it was more than 500 metric tons of leaves annually.


Iraq PM Visits Washington as U.S. Oil, Gas Deals Take Center Stage
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow
Dollar Slips as Oil Prices Ease, Fed Rate Outlook Remains Uncertain
US Stock Futures Slide as Iran Conflict Escalates Ahead of Key Q2 Earnings Week
Debate over H-1B visas shines spotlight on US tech worker shortages
Want to cut your energy bills? Here’s how five experts are doing it
Japanese Yen Rises as Pension Fund Plan and BOJ Rate Hike Bets Weigh on Dollar
Why financial hardship is more likely if you’re disabled or sick
Gold Prices Slip as U.S.-Iran Conflict, Fed Rate Hike Bets Pressure Precious Metals
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand
Stuck in a creativity slump at work? Here are some surprising ways to get your spark back
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth
Dollar Rises as Middle East Conflict Fuels Inflation and Rate Hike Fears
Japan Eyes Bigger GPIF Investment in Domestic Assets as BOJ Independence Concerns Grow
European Regulators Clash With U.S. Treasury Over Private Credit Transparency
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 



